Cite
Afolabi MO, Ishola D, Manno D, et al. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial. Lancet Infect Dis. 2021;doi: 10.1016/S1473-3099(21)00128-6.
Afolabi, M. O., Ishola, D., Manno, D., Keshinro, B., Bockstal, V., Rogers, B., Owusu-Kyei, K., Serry-Bangura, A., Swaray, I., Lowe, B., Kowuor, D., Baiden, F., Mooney, T., Smout, E., Köhn, B., Otieno, G. T., Jusu, M., Foster, J., Samai, M., Deen, G. F., Larson, H., Lees, S., Goldstein, N., Gallagher, K. E., Gaddah, A., Heerwegh, D., Callendret, B., Luhn, K., Robinson, C., Greenwood, B., Leyssen, M., Douoguih, M., Leigh, B., Watson-Jones, D. (2021). Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial. The Lancet. Infectious diseases, . https://doi.org/10.1016/S1473-3099(21)00128-6
Afolabi, Muhammed O, et al. "Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial." The Lancet. Infectious diseases vol. (2021). doi: https://doi.org/10.1016/S1473-3099(21)00128-6
Afolabi MO, Ishola D, Manno D, Keshinro B, Bockstal V, Rogers B, Owusu-Kyei K, Serry-Bangura A, Swaray I, Lowe B, Kowuor D, Baiden F, Mooney T, Smout E, Köhn B, Otieno GT, Jusu M, Foster J, Samai M, Deen GF, Larson H, Lees S, Goldstein N, Gallagher KE, Gaddah A, Heerwegh D, Callendret B, Luhn K, Robinson C, Greenwood B, Leyssen M, Douoguih M, Leigh B, Watson-Jones D. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial. Lancet Infect Dis. 2021 Sep 13; doi: 10.1016/S1473-3099(21)00128-6. Epub 2021 Sep 13. PMID: 34529962.
Copy
Download .nbib